U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H27N5O4
Molecular Weight 437.4916
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Cyclazosin, (+)-

SMILES

[H][C@]12CCCC[C@@]1([H])N(CCN2C(=O)C3=CC=CO3)C4=NC(N)=C5C=C(OC)C(OC)=CC5=N4

InChI

InChIKey=XBRXTUGRUXGBPX-DLBZAZTESA-N
InChI=1S/C23H27N5O4/c1-30-19-12-14-15(13-20(19)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)18-8-5-11-32-18/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26)/t16-,17+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18037913 | https://www.ncbi.nlm.nih.gov/pubmed/15598431

CYCLAZOSIN HYDROCHLORIDE is a quinazoline derivative pharmacologically characterized as putative a1B-adrenoceptor antagonist.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.24 nM [Ki]
12.3 nM [Ki]
0.135 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Synthesis and alpha(1)-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin.
2007 Mar 15
Patents

Sample Use Guides

Male C-57 WT mice (22–35 g) were injected s.c. with the putative a1B-adrenoceptor antagonist cyclazosin (1.0mg/kg). Cyclazosin was administered 30 min prior to the injection of vehicle (1 ml/kg) or MDMA (20mg/kg). The putative a1B-adrenoceptor antagonist cyclazosin (1mg/kg) in vehicle experiments did not significantly alter the body temperature when compared to vehicle group. The pretreatment of mice with cyclazosin significantly altered the effect of MDMA on core body temperature
Route of Administration: Topical
Sections of the abdominal aorta, obtained from adult female New Zealand rabbits, were treated with agonists and antagonists of adrenergic receptors. Administration of cyclazosin at a dose of 0.002 μM caused a decrease in the muscle tonus of -0.49 ± 0.10 mN. After blockade of the α1B-adrenergic receptor by 0.02 mkM cyclazosin, the administration of 0.05 μM phenylephrine resulted in an increase of the aortic muscle tonus of 1.49 ± 0.14 mN.
Name Type Language
Cyclazosin, (+)-
Common Name English
(+)-Cyclazosin
Common Name English
[(4aR,8aS)-4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)octahydro-1(2H)-quinoxalinyl]-2-furanylmethanone
Systematic Name English
(((4AR)-4-(4-AMINO-6,7-DIMETHOXYQUINAZOLINE-2-YL)-3,4,4A.BETA.,5,6,7,8,8A.BETA.-OCTAHYDROQUINOXALINE)-1(2H)-YL)(2-FURANYL) KETONE
Common Name English
J981.319E
Code English
Methanone, [(4aR,8aS)-4-(4-amino-6,7-dimethoxy-2-quinazolinyl)octahydro-1(2H)-quinoxalinyl]-2-furanyl-
Systematic Name English
(+)-2-((4AS,8AR)-4-(2-FUROYL)OCTAHYDROQUINOXALIN-1(2H)-YL)-6,7-DIMETHOXYQUINAZOLIN-4-AMINE
Systematic Name English
((4ar,8as)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)octahydroquinoxalin-1(2h)-yl)(2-furyl)methanone
Systematic Name English
Code System Code Type Description
PUBCHEM
132266
Created by admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
PRIMARY
CHEBI
63937
Created by admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID701112809
Created by admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
PRIMARY
FDA UNII
2FH26454WF
Created by admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
PRIMARY
CAS
210542-51-1
Created by admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
PRIMARY